Bliss GVS Pharma Shows Strong Financial Performance in Q1, PBT and PAT See Significant Growth

Bliss GVS Pharma, a smallcap pharmaceutical company, has recently announced its financial results for the quarter ended March 2024. The company has shown a positive performance in this quarter, with a significant improvement in its financial score from 5 to 12 in the last 3 months. One of the key highlights of the financial report is the growth in Profit Before Tax (PBT) less Other Income, which has increased by 626.81% year on year to Rs 19.65 crore. This indicates a very positive trend in the near term for PBT. Similarly, the Profit After Tax (PAT) has also shown a significant growth of 500.3% year on year to Rs 20.05 crore, with a positive trend in the near term. However, the company's Earnings per Share (EPS) for this quarter is the lowest in the last five quarters at Rs -0.87. This indicates a declining profitability and lower earnings for shareholders. MarketsMOJO has given a 'Hold' call for Bliss GVS Pharma's stock, taking into consideration its financial performance and other factors. With a positive trend in PBT and PAT, the company is expected to continue its growth in the near future. Investors are advised to hold their positions in the stock for now.